Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.150
-0.130 (-3.04%)
At close: Apr 28, 2026, 4:00 PM EDT
4.180
+0.030 (0.72%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Arbutus Biopharma Revenue
In the year 2025, Arbutus Biopharma had annual revenue of $14.08M with 128.21% growth. Arbutus Biopharma had revenue of $1.05M in the quarter ending December 31, 2025, a decrease of -33.23%.
Revenue (ttm)
$14.08M
Revenue Growth
+128.21%
P/S Ratio
58.03
Revenue / Employee
$741,211
Employees
19
Market Cap
817.30M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.08M | 7.91M | 128.21% |
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Theravance Biopharma | 107.46M |
| ARS Pharmaceuticals | 84.28M |
| MeiraGTx Holdings | 81.39M |
| Kura Oncology | 67.48M |
| Crescent Biopharma | 10.84M |
| Allogene Therapeutics | 22.00K |
ABUS News
- 13 days ago - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewsWire
- 5 weeks ago - Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ
- 2 months ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 2 months ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 2 months ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 2 months ago - Moderna Resolves Global Patent Litigation with Arbutus/Genevant - Accesswire
- 5 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire